The Japan Breast Cancer Therapeutics Market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 9.6% during the forecast period
The major factors that drive the market include the high prevalence of breast cancer and awareness programs by government and private organizations. According to the National Cancer Centre of Japan, breast cancer is the most common cancer in women. About 89,100 cases were reported in the country in 2017. Also, breast cancer is the 5th largest cause of mortality in Japan. About 14,400 casualties were reported in 2017. The increasing incidences enable the growth of the screening rates thus also allowing the growth of the market in this region. The ‘Pink Ribbon Festival’ initiated by the Japan Cancer Society enables to raise public awareness of the importance of early detection, diagnosis and treatment of breast cancer.
One of the foremost drivers influencing the growth of the global market is the increased prevalence of breast cancer across the country, which is expected to result in a large patient population demanding accurate and efficient treatment options. Breast cancer is one of the most prevalent forms of cancer and improved diagnostics are further expected to result in a greater number of patients being diagnosed.
Furthermore, the increasing demand for preventive care and early treatment has led many individuals to undergo cancer screening tests, which would also strongly drive the number of patients demanding treatment in the forecast period. Besides, the increasing patient awareness due to such alarming statistics is anticipated to further drive the market growth. Hence, the rising prevalence of breast cancer is projected to boost the market growth in the forecast period.
One of the critical factors that are expected to strongly propel the market growth in the forthcoming years is new product launches for the treatment of breast cancer by key players. These product launches are projected to positively impact the market as they are technologically advanced and may often result in better treatment outcomes for patients.
Additionally, some of the new product launches are specifically aimed at the treatment of breast cancer that was previously untreatable, or the earlier treatments were not successful in terms of improved outcomes for patients. Therefore, these factors are projected to positively impact the market during the forecast period.